Anemia news from FiercePharma
News
Did FDA counsel save Procrit ads?
Remember that DTC hearing in Congress last week, when Rep. Read more...
NC hospital nixes drug-sample handouts
While drugmakers and the Massachusetts legislature duke it out over the "no pharma freebies" Read more...
J&J laying off 400 in marketing overhaul
With Procrit under siege, Johnson & Johnson wants to divert its promotional efforts elsewhere--a strategy that will lead to some 400 job cuts in its sales-and-marketing ranks. The company told Read more...
Roche appeals Mircera injunction
Roche is appealing to a higher power on Mircera. The Swiss drugmaker is appealing a lower court ruling barring Read more...
Grassley: Amgen doc rebates skyrocket
Another day, another Grassley letter. You'll recall that earlier this week, Sen. Chuck Grassley demanded documents from Amgen relating to the company's promotions of its anemia drugs. Now, Grassley Read more...
Congress probes Amgen, J&J promos
Did Amgen and Johnson & Johnson over-promote their anemia drugs? Congress is asking the companies for documents detailing their advertising and promotions, including a "bundling" discount Amgen Read more...
Court sends Mircera case to ITC
Another chapter in what's becoming a long Mircera saga: A federal appeals court ruled that Roche could import the anemia drug so long as it wasn't for sale--but sent the case back to the Read more...
Amgen: Mircera deal would set precedent
Should he or shouldn't he? The judge weighing the case of Amgen v. Roche is getting a lot of unsolicited advice on whether to allow Roche's anemia med Mircera onto the market. Last year, a jury ruled Read more...
ALSO NOTED: Roche accepts judge's deal on Mircera; Pharma stocks weathered yesterday's craziness;
> Breaking news: Roche said it agreed to a judge's conditions for its launch of the anemia drug Mircera, which Amgen had attacked for patent infringement; the conditions include a higher royalty Read more...
J&J hikes CEO's pay to $25.1M
Another day, another CEO pay raise. Johnson & Johnson honcho Bill Weldon (photo) nabbed a 22 percent hike in compensation in Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight